ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 448,47
0,17%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Amylyx Pharmaceuticals Inc (AMLX)

  7. Amylyx Pharmaceuticals Inc (AMLX) Actualités

AMLX

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AMLX
DateHeureSourceTitreSymboleSociété
07/06/202422h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
06/06/202422h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/06/202415h00Business WireAmylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/05/202413h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/05/202413h00Business WireAmylyx Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/05/202415h00Business WireAmylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/05/202415h00Business WireAmylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/04/202415h00Business WireAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/04/202411h45PR Newswire (US)The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/04/202415h00Business WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/04/202411h45PR Newswire (US)Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/04/202413h00Business WireAmylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and StrategyNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/04/202411h45PR Newswire (US)The Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
29/03/202410h45PR Newswire (US)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) ShareholdersNASDAQ:AMLXAmylyx Pharmaceuticals Inc
26/03/202410h45PR Newswire (US)Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
25/03/202413h00PR Newswire (US)INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINENASDAQ:AMLXAmylyx Pharmaceuticals Inc
22/03/202410h45PR Newswire (US)The Gross Law Firm Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming DeadlineNASDAQ:AMLXAmylyx Pharmaceuticals Inc
19/03/202410h45PR Newswire (US)Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
14/03/202414h00Business WireAmylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of DirectorsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
14/03/202410h50PR Newswire (US)The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/03/202413h44Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/03/202410h50PR Newswire (US)Amylyx Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/03/202413h00Business WireAmylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALSNASDAQ:AMLXAmylyx Pharmaceuticals Inc
26/02/202411h45PR Newswire (US)AMLX LAWSUIT ALERT: The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:AMLXAmylyx Pharmaceuticals Inc
23/02/202422h05Business WireAmylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:AMLXAmylyx Pharmaceuticals Inc
22/02/202422h29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AMLXAmylyx Pharmaceuticals Inc
22/02/202414h22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
22/02/202413h00Business WireAmylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
15/02/202422h05Business WireAmylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
15/02/202415h00Business WireAmylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMLX

Dernières Valeurs Consultées

SPI
SP500
S&P 500
EU
CAP
Capgemini
EU
AI
Air Liquide
EU
EN
Bouygues
FTSE
UKX
FTSE 100
NYSE
NKE
Nike
EU
SGO
Cie de SaintGobain
EU
BEL20
Bel 20
EU
GLE
Societe Generale
NASDAQ
NVDA
NVIDIA
EU
ACA
Credit Agricole
COIN
BTCUSD
Bitcoin
NYSE
MCD
McDonalds
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés